Phuturdex › Listed companies › Incyte Corporation
Companies listed in the US · updated 13 November 2026
Incyte Corporation: drugs in development, dates and SEC filings
Data from official sources, not financial advice.
As of 13 November 2026 Incyte Corporation sponsors 53 active clinical trials (recruiting or ongoing, phases I–III) on 41 identified drugs. 17 are experimental (not yet approved in the United States), 6 in phase III.
Official links
Pipeline by phase
Drugs in the active trials sponsored by Incyte Corporation, with the most advanced phase of those trials. Sorted by phase and number of trials.
More drugs in development: 7. Drugs already approved in the US in the company’s trials: 24. Full list with trials, reference trial, dates, patents and events in Phuturdex. Sign up free to see everything →
Upcoming dates
Expected primary completion of the company’s phase II and III trials (12 months, date stated by the sponsor on ClinicalTrials.gov) and regulatory dates of the products the company holds (36 months). Below, the dates of the current month.
| Date | Drug | What | Source |
|---|---|---|---|
| Nov 2026 | Ruxolitinib | Expected primary completion of a phase II trial · NCT04509700 | ClinicalTrials.gov |
| Nov 2026 | Povorcitinib | Expected primary completion of a phase II trial · NCT05851443 | ClinicalTrials.gov |
Upcoming dates in all: 15. Sign up free to see everything →
US exclusivities and patents expiring
Products whose FDA application is held by the company (Orange Book or Purple Book), expiring in the next 36 months.
US patent and exclusivity expiries in the next 36 months: 3. Sign up free to see everything →
Recent events (last 12 months)
The company’s trials terminated, suspended or withdrawn and new phase III trials (ClinicalTrials.gov); approvals, opinions and designations of the products the company holds (FDA, EMA).
Events in the last 12 months: 7. The latest is shown below. Sign up free to see everything →
| Date | Drug | What | Source |
|---|---|---|---|
| Sep 2026 | INCA033989 | New phase III trial started (NCT07623200). | ClinicalTrials.gov |
Financial figures from the latest SEC report
Figures as reported by the company in its SEC filing (XBRL data), in the currency of the filing, with no Phuturdex calculation. Quarter: 10-Q report for the period ended 30 September 2026, filed 29 October 2026.
| Item | Value | Period | Filing |
|---|---|---|---|
| Cash and cash equivalentsus-gaap:CashAndCashEquivalentsAtCarryingValue | USD 3.28 billion | at 30 September 2026 | 10-Q · 29 Oct 2026 |
| Research and development expenseus-gaap:ResearchAndDevelopmentExpense | USD 1.79 billion | 1 July 2026 to 30 September 2026 | 10-Q · 29 Oct 2026 |
| Revenue from contracts with customersus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | USD 1.56 billion | 1 July 2026 to 30 September 2026 | 10-Q · 29 Oct 2026 |
Recent SEC filings
| Filing | Filed | Reference date |
|---|---|---|
| 10-Q | 29 Oct 2026 | 30 Sep 2026 |
| 8-K | 29 Oct 2026 | 29 Oct 2026 |
| 8-K | 31 Aug 2026 | 31 Aug 2026 |
| 10-Q | 28 Jul 2026 | 30 Jun 2026 |
| 8-K | 28 Jul 2026 | 28 Jul 2026 |
| 8-K | 6 Jul 2026 | 6 Jul 2026 |
All the data on Incyte Corporation
In Phuturdex you get every trial of the company with countries and dates, the catalyst calendar, email alerts when something changes and PDF and Excel export. Free until 31 March 2027.
Open in Phuturdex →Sources: SEC EDGAR (exchange, ticker, filings and XBRL financial data, US Government works); ClinicalTrials.gov (U.S. National Library of Medicine), FDA (Drugs@FDA, Orange and Purple Book, orphan drugs) and EMA, data processed by Phuturdex and updated 13 November 2026. Active trials = recruiting or ongoing, phases I–III. The sponsor is the one stated by each trial; company names are linked to the SEC only when they are the same apart from the legal form. Patents, exclusivities, approvals and opinions are attributed to the company only when it holds them in the official register. No stock prices or charts. Only the official sources are authoritative.
Data from official sources, not financial advice.